Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 18,485Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 5Vyndaqel/Vyndamax

PharmaCompass

01

Brand Name : Vyndaqel/Vyndamax

Tafamidis

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Vyndaqel/Vyndamax

arrow
Fi Europe 2024
Not Confirmed

Tafamidis

Main Therapeutic Indication : Rare Disorders

Currency : USD

2019 Revenue in Millions : 473

2018 Revenue in Millions : 148

Growth (%) : 220

blank

02

Brand Name : Vyndaqel/Vyndamax

Tafamidis

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Vyndaqel/Vyndamax

arrow
Fi Europe 2024
Not Confirmed

Tafamidis

Main Therapeutic Indication : Rare Disorders

Currency : USD

2020 Revenue in Millions : 1,288

2019 Revenue in Millions : 473

Growth (%) : 172

blank

03

Brand Name : Vyndaqel/Vyndamax

Tafamidis

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Vyndaqel/Vyndamax

arrow
Fi Europe 2024
Not Confirmed

Tafamidis

Main Therapeutic Indication : Rare Disorders

Currency : USD

2021 Revenue in Millions : 2,015

2020 Revenue in Millions : 1,288

Growth (%) : 56

blank

04

Brand Name : Vyndaqel/Vyndamax

Tafamidis

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Vyndaqel/Vyndamax

arrow
Fi Europe 2024
Not Confirmed

Tafamidis

Main Therapeutic Indication : Rare Diseases

Currency : USD

2022 Revenue in Millions : 2,447

2021 Revenue in Millions : 2,015

Growth (%) : 21

blank

05

Brand Name : Vyndaqel/Vyndamax

Tafamidis

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Vyndaqel/Vyndamax

arrow
Fi Europe 2024
Not Confirmed

Tafamidis

Main Therapeutic Indication : Rare Diseases

Currency : USD

2023 Revenue in Millions : 3,321

2022 Revenue in Millions : 2,447

Growth (%) : 36

blank